Gill A, Brunson A, Lara P, Khatri V, Semrad T J
Division of Hematology/Oncology, Department of Internal Medicine, University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Division of Surgical Oncology, Department of Surgery, University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Eur J Surg Oncol. 2015 May;41(5):647-52. doi: 10.1016/j.ejso.2015.01.037. Epub 2015 Mar 11.
In contrast to colon cancer, the implications of reduced lymph node retrieval in rectal cancer are unclear.
Using the California Cancer Registry, we performed a retrospective cohort study of 4790 patients with stage I - III rectal cancer diagnosed from 2000 to 2007 who underwent tri-modality therapy. Using multivariate Cox proportional hazards models adjusted for age, sex, race, socioeconomic status, T-stage, and lymph node numbers, we evaluated rectal cancer specific survival (RC-SS) in neoadjuvant and adjuvant cohorts in the overall population and amongst those without involved lymph nodes (pN0).
Sixty one percent of evaluable patients were treated with neoadjuvant chemoradiation. Although there was no difference in RC-SS between neoadjuvant and adjuvant chemoradiation cohorts, the median number of lymph nodes examined was reduced after neoadjuvant therapy (8 vs. 11, p < 0.0001). Positive lymph nodes were associated with worse RC-SS regardless of sequence, although the effect was numerically stronger for residual lymph nodes in the neoadjuvant cohort. Compared to at least 12, eight or fewer lymph nodes retrieved was associated with worse outcome in both neoadjuvant and adjuvant cohorts. However, no association between reduced lymph nodes examined and RC-SS was seen in the neoadjuvant cohort when the analysis was restricted to pN0 patients.
In this large cohort of rectal cancer patients treated with tri-modality therapy, reduced lymph node retrieval in node negative patients did not provide additional prognostic information in patients treated with neoadjuvant therapy.
与结肠癌不同,直肠癌中淋巴结清扫数量减少的影响尚不清楚。
利用加利福尼亚癌症登记处的数据,我们对2000年至2007年诊断为I - III期直肠癌并接受三联疗法的4790例患者进行了一项回顾性队列研究。我们使用多变量Cox比例风险模型,对年龄、性别、种族、社会经济地位、T分期和淋巴结数量进行了调整,评估了总体人群以及无淋巴结转移(pN0)患者的新辅助治疗组和辅助治疗组中的直肠癌特异性生存率(RC-SS)。
61%的可评估患者接受了新辅助放化疗。虽然新辅助放化疗组和辅助放化疗组的RC-SS没有差异,但新辅助治疗后检查的淋巴结中位数减少(8个对11个,p < 0.0001)。无论治疗顺序如何,阳性淋巴结都与较差的RC-SS相关,尽管新辅助治疗组中残留淋巴结的影响在数值上更强。与至少清扫12枚淋巴结相比,清扫8枚或更少淋巴结与新辅助治疗组和辅助治疗组的预后较差相关。然而,当分析仅限于pN0患者时,新辅助治疗组中检查的淋巴结减少与RC-SS之间没有关联。
在这个接受三联疗法治疗的大量直肠癌患者队列中,淋巴结阴性患者的淋巴结清扫数量减少并未为接受新辅助治疗的患者提供额外的预后信息。